European Medicines Agency signs four-year deal for AdisInsight
The European Medicines Agency (EMA) has signed a four-year agreement with Adis, a leading global provider of drug information, for AdisInsight, a database for drug research and development, disease treatment and decision making. Adis is part of the leading global scientific, technical and medical publisher Springer.
Mike Sumner, Director of Product Management for AdisInsight at Adis, said, "This is a landmark deal for AdisInsight as it demonstrates that we can deliver a first-rate experience for users of drug databases. EMA is a very important customer and their commitment to a four-year license is a strong endorsement of the improvements we have made with the new platform. We are very happy to be continuing our relationship with them over the coming years."
Based on trusted, scientifically sound data, AdisInsight brings together essential information on drugs in commercial development, key clinical trials, deals undertaken and safety profiles in one database. It is available for preview at adisinsight.springer.com
EMA announced earlier this year that they were seeking a comprehensive drug database to provide scientific, economic and industry-related information. Although EMA had been using the old Adis databases for two years, the publisher was required to submit a new tender as part of the Agency's procurement process. Database users within the Agency will now begin integrating the new AdisInsight platform into their workflows with support from the AdisInsight product experts who will be on hand to deliver training and guidance.
The European Medicines Agency (EMA) is a decentralized agency of the European Union, located in London. The EMA's main responsibility is the protection and promotion of public and animal health through the evaluation and supervision of medicines for human and veterinary use.
Adis offers a reputable and independent portfolio of medical journals and business intelligence solutions for healthcare professionals, researchers, decision makers and drug developers. AdisInsight presents a unique, joined-up view of current evidence on drug treatments being developed worldwide — how well they work, how safe they are, who is working on them, and how soon they will be available — in a single database.
Springer is part of Springer Nature, a leading global research, educational and professional publisher, home to an array of respected and trusted brands providing quality content through a range of innovative products and services. Springer Nature is the world's largest academic book publisher, publisher of the world's highest impact journals and a pioneer in the field of open research. The company numbers almost 13,000 staff in over 50 countries and has a turnover of approximately EUR 1.5 billion. Springer Nature was formed in 2015 through the merger of Nature Publishing Group, Palgrave Macmillan, Macmillan Education and Springer Science+Business Media.
Find out more: http://www.springernature.com